BioVie
BIVI
BioVie (BIVI) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| ThinkEquity | Initiated Coverage | Buy | $3.00 | Jul 1, 2024 |
| Oppenheimer | Maintained | Outperform | $5.00 from $12.00 | Nov 30, 2023 |
| Cantor Fitzgerald | Maintained | Overweight | $11.00 | Aug 22, 2023 |
| Cantor Fitzgerald | Maintained | Overweight | $11.00 | Jul 18, 2023 |
| Cantor Fitzgerald | Maintained | Overweight | $11.00 | May 17, 2023 |
| Oppenheimer | Maintained | Outperform | $12.00 | May 17, 2023 |
Frequently asked questions
What is the latest analyst rating on BIVI?
On Jul 1, 2024, ThinkEquity initiated coverage of BioVie at Buy with a price target of $3.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.